Investing in the 1st Domestic Producer of Medical Isotopes

Over the past several years, Advanced Medical Isotope Corporation (OTCBB: ADMD) has positioned itself to become the leading domestic Company in the fast-growing field of Nuclear Medicine known as Medical Isotopes.

ADMD is engaging in the production and distribution of medical isotopes, such as Molybdenum-99 (Mo-99), as well as medical isotope in vivo delivery systems for advanced diagnostic and non-surgical therapeutic applications.

What are Medical Isotopes? A medical isotope is a radioactive substance used in very small quantities for safe, cost-effective medical imaging and treatment of disease. New technologies enable therapeutic isotopes to be delivered directly to the site of diseased cells. This is different from external beam radiation treatment where radiation is directed from outside the body.

What is Molybdenum-99 (Mo-99)? Mo-99 is the most commonly used medical isotope in the world and is facing a critical shortage due to a small number of processing facilities and aging reactors. In response to this ongoing crisis, ADMD is developing methods to produce Mo-99 and other radioisotopes without needing a nuclear reactor, instead using a device the approximate size of a commercial cyclotron for production. ADMD has development programs in place to produce Mo-99 with high yields at a significant reduction in cost compared to isotopes made from nuclear plant methods.

ADMD's Management team includes prominent industry scientists and highly experienced members in business management, medical technology startup firms, and the nuclear technology industry. The senior management team averages over 30 years experience in the nuclear and technology industries, each with extensive experience performing the specific roles assigned within AMIC.

The global market for Oxygen-18 (O-18), a rare and stable isotope target for making the PET isotope Flourine-18 (F-18), is approx. $38M and has been growing almost 20% annually. The market for PET-specific isotopes is currently over $1B, growing over 25% annually, providing a great opportunity for AMIC to position itself as a major supplier of O-18 to other major F-18 FDG manufacturers.

ADMD is currently shipping stable isotopes worldwide is developing a proprietary production method to manufacture Molybdenum 99 (Mo-99) a method which the Company believes will be the fastest and least expensive with highest yield to solve the current critical shortage of Mo-99.

Comprised of top industry experts for isotope production and application, ADMD offers investors an opportunistic investment vehicle to participate in the explosive field of medical isotopes.